Evidence map›Paper›PMID 26627223›Full record

ReviewCurrent obesity reports2015

Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.

J Grams, W Timothy Garvey

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current obesity reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Change in Inflammatory Biomarkers and Adipose Tissue inCancer prevention research (Philadelphia, Pa.) · 2018
    Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

J GramsDepartment of Surgery, University of Alabama at Birmingham and the Birmingham VA Medical Center, KB401, 1720 2nd Ave S, Birmingham, AL, 35294-0016, USA. jgrams@uab.edu.
W Timothy GarveyDepartment of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham VA Medical Center, 1675 University Boulevard, Birmingham, AL, 35294-3360, USA. garveyt@uab.edu.
University of Alabama at Birmingham · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
MECHANISMS OF HUMAN INSULIN RESISTANCER01DK038765 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GARVEY, W TIMOTHY · 1993 to 2010
$4.0M
NR4A Orphan Receptors And Insulin ResistanceR01DK083562 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GARVEY, W TIMOTHY · 2009 to 2012
$2.1M
ROLE OF GLUCOSE TRANSPORT PROTEINS IN DIABETES MELLITUSR29DK038765 · NIDDK · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GARVEY, W TIMOTHY · 1988 to 1992
–
NIDDK NIH HHS DK-038765NIDDK NIH HHS DK-083562NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

Weight loss, whether achieved by lifestyle intervention, pharmacotherapy, or bariatric surgery, is highly effective as a primary interventional strategy in both the prevention and treatment of type 2 diabetes. In high-risk patients with prediabetes and/or metabolic syndrome, weight loss effectively prevents progression to type 2 diabetes mellitus (T2DM) and improves cardiovascular risk factors. These benefits are the result of improvements in insulin resistance, which is central to the pathophysiology of cardiometabolic disease. In patients with T2DM, weight loss improves glycemia, while reducing the need for conventional glucose-lowering medicines, by affecting all three processes that produce and sustain the hyperglycemic state, namely via increments in peripheral insulin sensitivity with improvements in insulin signal transduction at the cellular level, more robust insulin secretory responses, and reduced rates of hepatic glucose production. In both nondiabetic and diabetic subjects, hypocaloric feeding (e.g., treatment with very low-calorie diet or bariatric surgery) produces a rapid improvement in insulin sensitivity due to mobilization of fat from the intramyocellular, intrahepatocellular, and intra-abdominal compartments, and via a more long-term mechanism that correlates with the loss of total body fat. In diabetes, by improving glycemia, weight loss also enhances glucose homeostasis by reversing the defects in insulin action and secretion attributable to glucose toxicity. Regardless of the therapeutic approach, weight loss of ∼ 10 % maximally prevents future diabetes in patients with prediabetes or metabolic syndrome. In T2DM, greater degrees of weight loss lead to progressive improvements in glucose homeostasis. Therefore, when accompanied by greater weight loss, the metabolic benefits following bariatric surgery are generally more pronounced than those achieved following lifestyle and medical treatment. In addition, the mechanisms by which bariatric operations improve diabetes may include both weight-dependent and weight-independent mechanisms, and the latter may involve changes in gut hormones, bile acids, or gut microflora.

Indexed as

Bariatric SurgeryLife StyleAdipose TissueAnti-Obesity AgentsBlood GlucoseDiabetes Mellitus, Type 2HumansInsulinInsulin ResistanceObesityWeight LossAnti-Obesity AgentsBlood GlucoseInsulinBariatric surgeryDiabetesLifestyle interventionMechanism of actionMetabolic syndromeObesityObesity medicationsPrediabetesWeight loss

Identifiers

PMID26627223
OpenAlexW2092730639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.